News
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
17h
Zacks Investment Research on MSNCI's Unit Unveils Offering to Expand Access to GLP-1 MedicationsThe health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...
As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.
Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...
The U.S. Environmental Protection Agency has drafted a plan to eliminate all limits on greenhouse gases from coal and ...
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results